(PDF) P1.01-39 Cost-Effectiveness of Crizotinib Versus

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.595

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management

English

P1.01-101 Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance

Journal of Thoracic Oncology

Respiratory Medicine

English

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology

Cancer Research

English

Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey

Value in Health

Occupational Health

English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Cancer Research

English

P2.01-109 Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English